Next Article in Journal
Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound
Next Article in Special Issue
Deregulation of Interferon Signaling in Malignant Cells
Previous Article in Journal
Nitric Oxide Synthase Inhibitors as Antidepressants
Previous Article in Special Issue
Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.

Oromucosal Administration of Interferon to Humans

School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, 35 Stirling Highway, Crawley WA 6009, Australia
Amarillo Biosciences, Inc., 4134 Business Park Drive, Amarillo, TX 79110, USA
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(2), 323-344;
Received: 1 December 2009 / Revised: 20 January 2010 / Accepted: 25 January 2010 / Published: 28 January 2010
(This article belongs to the Special Issue Interferons)
The prevailing dogma is that, to be systemically effective, interferon-alpha (IFNα) must be administered in sufficiently high doses to yield functional blood concentrations. Such an approach to IFNa therapy has proven effective in some instances, but high-dose parenteral IFNα therapy has the disadvantage of causing significant adverse events. Mounting evidence suggests that IFNα delivered into the oral cavity in low doses interacts with the oral mucosa in a unique manner to induce systemic host defense mechanisms without IFNα actually entering the circulation, thus reducing the potential for toxic side effects. A better understanding of the applications and potential benefits of this treatment modality are under active investigation. This paper provides a review of the relevant literature on the clinical use of the oromucosal route of administration of interferon, with an emphasis on the treatment of influenza. View Full-Text
Keywords: interferon; oromucosal delivery; influenza; treatment; viral diseases interferon; oromucosal delivery; influenza; treatment; viral diseases
MDPI and ACS Style

Beilharz, M.W.; Cummins, M.J.; Bennett, A.L.; Cummins, J.M. Oromucosal Administration of Interferon to Humans. Pharmaceuticals 2010, 3, 323-344.

AMA Style

Beilharz MW, Cummins MJ, Bennett AL, Cummins JM. Oromucosal Administration of Interferon to Humans. Pharmaceuticals. 2010; 3(2):323-344.

Chicago/Turabian Style

Beilharz, Manfred W., Martin J. Cummins, Alayne L. Bennett, and Joseph M. Cummins 2010. "Oromucosal Administration of Interferon to Humans" Pharmaceuticals 3, no. 2: 323-344.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop